2021-03-25
View detailed financial information, real-time news, videos, quotes and analysis on Protara Therapeutics, Inc. (NASDAQ:TARA). Explore commentary on Protara Therapeutics, Inc. and hear what the
The institutional investor owned 17,110 shares of the company’s stock after selling 20,676 shares during the period. Renaissance Technologies LLC owned approximately 0.15% of […] Protara Therapeutics, Inc. is a clinical-stage company engages in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. 2021-03-05 · View today's stock price, news and analysis for Protara Therapeutics Inc. (TARA). Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation PROTARA THERAPEUTICS, INC. : News, information and stories for PROTARA THERAPEUTICS, INC. | Nasdaq: TARA | Nasdaq 2021-03-21 · Currently, the analyst consensus on Protara Therapeutics is a Moderate Buy with an average price target of $41.50, a 136.1% upside from current levels.
Get Protara Therapeutics Inc (TARA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. 2021-04-06 2021-03-25 Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. 2020-10-02 Protara Therapeutics, Inc. is a clinical-stage company engages in developing treatments for rare and specialty diseases with significant unmet needs. Stocks Rankings for TARA. Get the latest Protara Therapeutics Inc (TARA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Protara Therapeutics, Inc. Common Stock, also called Protara Therapeutics, is a clinical-stage company engages in developing treatments for rare and specialty diseases with significant unmet needs.
New York, NY 10010 (Name and address of agent for service) (646) 844-0337 (Telephone number, including area code, of agent for service) Protara Therapeutics Company Profile. Protara Therapeutics, Inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases.
Steadfast and tenacious in our search for transformative therapies TARA-002 TARA-002 is the Company's lead investigational cell therapy based on the broad
2021-04-06 2021-03-25 Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations.
Find the latest Protara Therapeutics, Inc. (TARA) stock quote, history, news and other vital information to help you with your stock trading and investing.
$-0.830. The average consensus EPS for TARA is $-0.830 with a high 19 Jun 2020 It pulled back during afternoon trading, up 95% and closing at 39 on the stock market today. Forma Therapeutics IPO priced 13.8 million shares at 20 Mar 2021 KTRA Stock Kintara Therapeutics Could Triple By End of Year! Rare Disease and Orphan FDA Fastrack!Text Me: (949) 415-6256My podcast is This means that share ownership of 13D/G filings and 13F filings are oftentimes not directly comparable, so we present them separately.
See charts, data and financials for Protara Therapeutics Inc TARA. Company Profile. Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The
View the latest Protara Therapeutics Inc. (TARA) stock price, news, historical charts, analyst ratings and financial information from WSJ.
3 days ago intratio.com/stock-forecast Protara Therapeutics Inc The mathematical model foretells the market value of this company will have a negative
Information on stock, financials, earnings, subsidiaries, investors, and executives for Protara Therapeutics. Use the PitchBook Platform to explore the full profile.
How to write classical music
Get Protara Therapeutics Inc (TARA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. 2021-04-06 2021-03-25 Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations.
NEW YORK, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the pricing of
View today's stock price, news and analysis for Protara Therapeutics Inc. (TARA).
Hundfrisör norrköping
kockjobb kopenhamn
lena rosendahl sandviken
valutaomvandlare forex dollar
global solutions network
2020-09-22 · NEW YORK, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases
The average consensus EPS for TARA is $-0.830 with a high 19 Jun 2020 It pulled back during afternoon trading, up 95% and closing at 39 on the stock market today. Forma Therapeutics IPO priced 13.8 million shares at 20 Mar 2021 KTRA Stock Kintara Therapeutics Could Triple By End of Year! Rare Disease and Orphan FDA Fastrack!Text Me: (949) 415-6256My podcast is This means that share ownership of 13D/G filings and 13F filings are oftentimes not directly comparable, so we present them separately.